<DOC>
	<DOCNO>NCT00377455</DOCNO>
	<brief_summary>The purpose study determine whether drug Bosentan improve exercise tolerance scleroderma patient .</brief_summary>
	<brief_title>Placebo Controlled Trial Bosentan Scleroderma Patients</brief_title>
	<detailed_description>Pulmonary hypertension ( PAH ) common usually fatal form lung disease systemic sclerosis ( SSc ) . Multiple drug approve treatment New York Heart Association ( NYHA ) Class III/IV PAH scleroderma . Bosentan endothelin-1 antagonist show significant improvement distance walk 12 week clinical trial PAH patient ( 7 ) . Therapy asymptomatic systemic sclerosis patient diagnose incidentally PAH ( World Health Organization ( WHO ) Functional Class I ) remain controversial . We hypothesize asymptomatic minimally symptomatic patient systemic sclerosis normal rest pulmonary artery pressure demonstrate abnormal rise pulmonary artery systolic pressure stress Doppler echocardiography test represent subset patient already pulmonary vascular disease risk development severe PAH . We hypothesize early identification treatment patient may retard progression disease . Hypotheses : 1 . Stress echocardiography identifies early pulmonary vascular disease detect exercise-induced pulmonary hypertension patient systemic sclerosis . 2 . Treatment exercise-induced PAH Bosentan lead improve exercise endurance patient systemic sclerosis . Subjects recruit patient abnormal exercise test part earlier study , Exercise Echocardiograms Scleroderma ( IRB # 03-363 ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>SSc patient &gt; 18 NYHA functional Class I/II symptom , informed consent , willing participate Pulmonary Hypertension Assessment Recognition Outcomes Scleroderma ( PHAROS ) long term study ( Georgetown IRB 04227 ) Right heart catheterization 1 . Normal Mean Pulmonary Arterial Pressure ( PAP ) rest 2 . Mean PAP &gt; 30 exercise 3 . Wedge Pressure &lt; 18 Entry criterion participate exercise echocardiogram study ( Georegtown IRB 03363 ) 1 . Diffusing Capacity ( DLCO ) &lt; 60 Forced Vital Capacity ( FVC ) &gt; 60 % , 2 . FVC/DLCO &gt; 1.6 , 3. rest Pulmonary Arterial Systolic Pressure ( PASP ) &gt; 40mmHg Established rest pulmonary hypertension Congestive heart failure Diastolic dysfunction Pregnancy Inability adequately walk/exercise Severe liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>scleroderma</keyword>
	<keyword>systemic sclerosis</keyword>
	<keyword>bosentan</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>PHAROS</keyword>
	<keyword>PHROS</keyword>
	<keyword>exercise echocardiogram</keyword>
</DOC>